Pfizer, Inc.

Pfizer, Inc.

Pfizer, Inc.

Overview
Date Founded

1849

Headquarters

235 East 42nd Street, New York, NY, 10017, USA

Type of Company

Public

Employees (Worldwide)

88.3K

Industries

Pharmaceuticals
Wholesale: Consumer Non-Durables/Sundries
Medical Products & Equipment
Hospitals & Patient Services
Medical Support Services
Biotechnology

Company Description

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Contact Data
Trying to get in touch with decision makers at Pfizer, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Chief Financial Officer

Chief Financial Officer & Executive Vice President, Global Supply

Executive Vice President & General Counsel

Executive Vice President, Chief Digital & Technology Officer

Chief Development Officer & Executive Vice President

Chief Scientific Officer & President, Worldwide Research, Development & Medical

Senior Vice President & Chief Scientific Officer, Internal Medicine Research Unit

Senior Vice President & Chief Scientific Officer-Rare Disease Research Unit

Senior Vice President & Chief Scientific Officer-Inflammation & Immunology Research Unit

Board of Directors

Chief Executive Officer at Pfizer, Inc.

President & Chief Executive Officer at Adobe, Inc.

President & Chief Executive Officer at Thomson Legal & Regulatory, Inc.

Philip O'Bryan Montgomery Junior, MD, Distinguished Chair in Developmental Biology at The University of Texas - Southwestern Medical Center

Member, Leadership Team at Eli & Edythe Broad Foundation

Co-Founder at Fieldpoint Private Bank & Trust

Former Deputy Managing Partner at Deloitte LLP

Founding Member/Managing Member/Executive Officer at GenNx360 Management Co. LLC

President Emeritus at Massachusetts Institute of Technology

Special Partner, Washington DC at New Enterprise Associates

Paths to Pfizer, Inc.
Potential Connections via
Relationship Science
You
Pfizer, Inc.
Owners & Shareholders
Details Hidden

SSgA FM’s methods of analysis include quantitative, fundamental, technical, cyclical, indexing, arbitrage, charting and other strategy specific methods. They offer a broad range of strategies including: Active, Enhanced, and Passive Equity; Active & Passive Debt; Cash Management; Multi-Asset Class Solutions; Real Estate (including Direct Real Estate); Senior Loans; Managed Futures; and Private Equity. Active equity strategies include enhanced equity and active quantitative strategies. The strategies cover market-cap and style segments of the market including: large-cap core, large-cap growth, large-cap value, mid-cap, small-cap, small-cap value, all-cap, and long-short equity. They also manage long-short and long-short market neutral strategies. SSgA FM’s Active & Passive Debt strategies offers a range of investment styles from passive to active, short to long duration, tax-exempt, sovereign to high yield, and single country to global. The firm’s Cash Management strategies seek to generate current income while preserving capital and liquidity by investing in diversified portfolios of short-term securities. SSgA FM's Multi-Asset Class strategies employ an asset allocation model as means of diversification and seek to position assets among major investment categories. Their Multi Asset Class Solutions strategies employ an asset allocation model as a method of diversification that aims to position assets among major investment categories. SSgA FM’s Managed Futures strategy allocates assets using two approaches: a managed futures strategy and a fixed income strategy. The firm’s Private Equity strategies focus on rigorous partner selection, thorough evaluation of quality investment opportunities, and fundamental, research-driven research.

Details Hidden

CWI employs a long-term, value-oriented global investment approach and a multiple portfolio manager system that combines teamwork and individual accountability. The firm utilizes fundamental research to gather in-depth information on markets and companies around the world. They also employ a security-by-security approach to portfolio construction and emphasize long-term investments. Their strategies focus on determining the difference between the fundamental value of a company and its price in the marketplace. CWI offers a wide variety of equity, fixed-income and balanced investment strategies. Their strategies are categorized as global, multi-regional and regional investment strategies.

Details Hidden

WMC relies on their extensive independent research and include portfolio management styles and approaches in equities, fixed income securities, currencies and commodities, as well as asset allocation across these categories. The firm has a number of different disciplines when approaching research and these include asset allocation analysts, currency analysts, data scientists, factor analysts, fixed income credit analysts, fixed income market analysts, global industry analysts and research associates, macro-analysts, quantitative analysts and technical analysts. WMC’s portfolio management teams often include dedicated analysts who evaluate securities and other instruments for suitability based on the team’s investment approach. The firm supplements their internal research with external research from sources such as broker/dealers and third-party research firms. These sources typically provide data, research and analysis and may serve as a gauge of market consensus.

Recent Transactions
Details Hidden

GlaxoSmithKline Plc purchases Pfizer, Inc. /Consumer Health Business from Pfizer, Inc.

Details Hidden

Pfizer, Inc. purchases Array BioPharma Inc.

Details Hidden

Pfizer, Inc. purchases TherAchon SAS from Pfizer Venture Investments, Triartisan Capital Advisors LLC, Versant Venture Management LLC, Sofimac Innovation SAS, New Enterprise Associates, Novo Ventures 1 A/S, BPIFrance Investissement SAS, OrbiMed Advisors Private Equity

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Legal Advisor

Advised onPfizer, Inc. purchases Warner-Lambert Co.

Legal Advisor

Advised onPfizer, Inc. purchases Warner-Lambert Co.

Accountant

Advised onPfizer, Inc. purchases Pharmacia Corporation

Legal Advisor

Advised onJohnson & Johnson purchases Pfizer, Inc. /Consumer Healthcare Business from Pfizer, Inc.

Attorney

Advised onPfizer, Inc. purchases Warner-Lambert Co.

Legal Advisor

Advised onPfizer, Inc. purchases Rinat Neuroscience Corp.

Advisors & Consultants
Advisor

Head, Corporate Communications at Wells Fargo & Co.

Legal Advisor

Partner at Jones Day

Legal Advisor

Senior Chairman at Greenberg Traurig LLP

Clients

Henry Schein, Inc., a FORTUNE 500® company and a member of the NASDAQ 100® Index, is the largest provider of health care products and services to medical, dental, and veterinary office-based practitioners. The Company is one of Fortune Magazine's "World’s Most Admired Companies", and is ranked number 1 in its industry in social responsibility and global competitiveness. Now more than ever, health care providers require specialized products and services to operate their practices efficiently. We offer an extensive selection of dental supplies, medical supplies, pharmaceuticals, vaccines, equipment, software technology, and much more. Our portfolio of practice solutions is designed to support our customers and to successfully meet their business goals and achieve optimal patient satisfaction

Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment comprises of portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs, and vaccines as well as diagnosis of disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment gives diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment involves in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Key Stats and Financials As of 2019
Market Capitalization
$213B
Total Enterprise Value
$266B
Earnings Per Share
$2.87
Revenue
$51.8B
Net Profit
$16.3B
EBITDA
$20.1B
EBITDAMargin
38.89%
Total Debt
$53.5B
Total Equity
$63.4B
Enterprise Value Sales
5.15x
Enterprise Value EBITDAOperating
13.17x
TEVNet Income
16.37x
Debt TEV
0.2x
Three Year Compounded Annual Growth Rate Of Revenue
-0.68%
Five Year Compounded Annual Growth Rate Of Revenue
0.85%
Non-Profit Donations & Grants
Non-Profit Donations & Grants Received
$13.1K
12/31/2012
Political Donations
$2,500 - $10K
2015
$300
1998
$250
1997
Investments
Details Hidden

Gliknik, Inc. discovers and develops biotechnology drugs for autoimmune diseases and cancer. The company was founded by David S. Block and Scott E. Strome in 2007 and is headquartered in Baltimore, MD.

Details Hidden

AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands.

Details Hidden

iCardiac Technologies, Inc, provides pharmaceutical cardiac safety trial services. It offers phase I QT assessment, TQT studies, phase II-IV cardiac, safety, spirometer, electronic clinical and outcome assessments. The company was founded by Alex Zapesochny, Jay B. Baker, Jean-Philippe Counderc, Alexandra Latypova, Wojciech Zareba and Mikael J. Totterman in 2006 and is headquartered in Rochester, NY.

Investors
Details Hidden

Life Peer at United Kingdom House of Lords

Details Hidden

Managing Director at Precision BioVentures LLC

Details Hidden

Investor at Fluidigm Corp.

Suppliers
RCM Technologies, Inc. Engineering, Construction & Architecture | Pennsauken, New Jersey

RCM Technologies, Inc. engages in the provision of business and technology solutions. It operates through the following business segments: Engineering, Specialty Health Care, Information Technology, and Corporate. The Engineering segment comprises of engineering, design, engineering analysis, technical writing, and technical support services. The Specialty Health Care Services segment offers staffing of health care professionals. The Information Technology segment involves the enterprise business solutions, application services, infrastructure solutions, competitive advantage and productivity solutions, life sciences solutions, and other selected vertical market specific offerings. The company was founded by Leon Kopyt in 1971 and is headquartered in Pennsauken, NJ.

Alexandria Real Estate Equities, Inc. Trusts & Funds | Pasadena, CA

Alexandria Real Estate Equities, Inc. is an urban office real estate investment trust, which engages in the ownership, operation, development, and redevelopment of life science and technology properties. It also provides a space for lease to the life science and technology industries which are primarily located in AAA urban innovation cluster locations. The company was founded by Alan D. Gold, Gary A. Kreitzer, Joel S. Marcus, and Jerry M. Sudarsky in October 1994 and is headquartered in Pasadena, CA.

Bioanalytical Systems, Inc. Medical Support Services | West Lafayette, IN

Bioanalytical Systems, Inc. operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The firm operates through the following business segments: Contract Research Services and Research Products. The Contract Research Services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing. The Research Products segment designs, develops, manufactures, and markets vivo sampling systems and accessories, physiology monitoring tools, liquid chromatography, and electrochemistry instruments platforms. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Awards & Honors
Rank #55
2016
Fortune Magazine - Fortune 1000 Companies
Sponsored by Fortune Magazine
Rank #55
2016
Fortune Magazine - Fortune 500 Companies
Sponsored by Fortune Magazine
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Pfizer, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Pfizer, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Pfizer, Inc..